Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dalmitamig
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Dalmitamig** is a humanized IgG4-kappa bispecific monoclonal antibody that simultaneously targets epidermal growth factor receptor (**EGFR**, also known as **HER1**) on tumor cells and **CD28** on T cells. Developed by **Regeneron Pharmaceuticals**, it functions as a first-in-class costimulatory bispecific antibody designed to inhibit EGFR-driven tumor growth while activating T-cell responses to enhance anti-tumor immunity, particularly in immunologically "cold" tumors like microsatellite-stable colorectal cancer. It is being evaluated in combination with cemiplimab (**Libtayo**, an anti-PD-1 antibody) for advanced solid tumors.
- Other names
- anti-EGFR/CD28 bispecific antibody REGN7075
02
Targets
CD28 (Cluster of Differentiation 28)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on dalmitamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dalmitamig.